- Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer
- Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare Conference
- Revance Receives Great Place to Work Certification
- Revance Releases Second Quarter 2018 Results
- Revance Therapeutics to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018
Revance Therapeutics Inc (RVNC:NMQ) closed at 24.85, 11.69% above the 52 week low of 22.25 set on Sep 14, 2018.
22.25Sep 14 201837.45Jan 03 2018
Markit short selling activity
|Market cap||883.55m USD|
|EPS (TTM)||-4.07 |
Data delayed at least 15 minutes, as of Oct 16 2018 21:00 BST.